Overall, DPP-4 inhibitors are less favored over the new antidiabetic agents (e.g., GLP-1RAs and SGLT2is), some benefits in HFmrEF are still limited by the data within the T2DM population. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.